Data / Drug companies / Indoco Remedies Limited
Indoco Remedies Limited: 58 products in the FDA NDC directory, labeler code 14445
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Indoco Remedies Limited (labeler code 14445) lists 58 products in the FDA National Drug Code Directory, covering 14 finished drugs by generic name. By type: 33 prescription drugs, 24 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 11, 2025.
The request: Watch Indoco Remedies Limited (FDA labeler code 14445): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 14445
- Products in commercial distribution
- 58
- Packages
- 253
- Finished drugs by generic name
- 14
- Prescription products
- 33
- Over the counter products
- 1
- Controlled substance products
- Schedule V 16
- Flagged as original packager
- 34 of 34 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- January 15, 2008
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 34 | 58.6% |
| Bulk ingredients | 24 | 41.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 33 | 56.9% |
| Bulk ingredients | 24 | 41.4% |
| Over the counter drugs | 1 | 1.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Pregabalin | 8 | 54 |
| Lacosamide | 5 | 57 |
| Rivaroxaban | 4 | 24 |
| Varenicline tartrate | 3 | 23 |
| Allopurinol | 3 | 54 |
| Apixaban | 2 | 8 |
| Neostigmine methylsulfate | 2 | 24 |
| Lofexidine | 1 | 3 |
| Ddorzolamide hydrochloride timolol maleate | 1 | 1 |
| Brimonidine tartrate | 1 | 15 |
| Succinylcholine chloride | 1 | 27 |
| Acetylcysteine | 1 | 15 |
| Cetirizine hydrochloride | 1 | 119 |
| Dorzolamide | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 23 | 39.7% |
| Tablet, film coated | 9 | 15.5% |
| Capsule | 8 | 13.8% |
| Tablet | 7 | 12.1% |
| Injection | 5 | 8.6% |
| Solution/ drops | 3 | 5.2% |
| Tablet, coated | 1 | 1.7% |
| Kit | 1 | 1.7% |
| Powder, for solution | 1 | 1.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Rivaroxaban | 14445-184 | Tablet, film coated | Generic drugs (ANDA) | August 11, 2025 |
| Rivaroxaban | 14445-183 | Tablet, film coated | Generic drugs (ANDA) | August 11, 2025 |
| Rivaroxaban | 14445-148 | Tablet, film coated | Generic drugs (ANDA) | August 11, 2025 |
| Rivaroxaban | 14445-147 | Tablet, film coated | Generic drugs (ANDA) | August 11, 2025 |
| Gliclazide | 14445-025 | Powder | Bulk ingredients | December 19, 2024 |
| Varenicline | 14445-155 | Kit | Generic drugs (ANDA) | November 1, 2024 |
| Varenicline tartrate | 14445-154 | Tablet, film coated | Generic drugs (ANDA) | November 1, 2024 |
| Varenicline tartrate | 14445-153 | Tablet, film coated | Generic drugs (ANDA) | November 1, 2024 |
| Cetirizine hydrochloride | 14445-152 | Tablet, film coated | Generic drugs (ANDA) | October 4, 2024 |
| Lofexidine | 14445-146 | Tablet, coated | Generic drugs (ANDA) | August 21, 2024 |
| Pregabalin | 14445-174 | Capsule | Generic drugs (ANDA) | May 17, 2024 |
| Pregabalin | 14445-173 | Capsule | Generic drugs (ANDA) | May 17, 2024 |
| Pregabalin | 14445-128 | Capsule | Generic drugs (ANDA) | May 17, 2024 |
| Pregabalin | 14445-127 | Capsule | Generic drugs (ANDA) | May 17, 2024 |
| Pregabalin | 14445-126 | Capsule | Generic drugs (ANDA) | May 17, 2024 |
| Pregabalin | 14445-125 | Capsule | Generic drugs (ANDA) | May 17, 2024 |
| Pregabalin | 14445-124 | Capsule | Generic drugs (ANDA) | May 17, 2024 |
| Pregabalin | 14445-123 | Capsule | Generic drugs (ANDA) | May 17, 2024 |
| Allopurinol | 14445-172 | Tablet | Generic drugs (ANDA) | May 15, 2024 |
| Rivaroxaban | 14445-026 | Powder | Bulk ingredients | March 15, 2024 |
| Rivaroxaban | 14445-024 | Powder | Bulk ingredients | March 15, 2024 |
| Lacosamide | 14445-023 | Powder | Bulk ingredients | March 6, 2024 |
| Lacosamide | 14445-406 | Injection | Generic drugs (ANDA) | April 9, 2022 |
| Lacosamide | 14445-132 | Tablet | Generic drugs (ANDA) | March 20, 2022 |
| Lacosamide | 14445-131 | Tablet | Generic drugs (ANDA) | March 20, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.